{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "EUR", "marketState": "REGULAR", "regularMarketChangePercent": 10.466583, "regularMarketPrice": 1.752, "exchange": "FRA", "shortName": "GLYCOMIMETICS INC. DL-001", "longName": "GlycoMimetics, Inc.", "messageBoardId": "finmb_5703481", "exchangeTimezoneName": "Europe/Berlin", "exchangeTimezoneShortName": "CEST", "gmtOffSetMilliseconds": 7200000, "market": "dr_market", "esgPopulated": false, "regularMarketTime": 1683893237, "earningsTimestamp": 1683117000, "earningsTimestampStart": 1690893000, "earningsTimestampEnd": 1691411400, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -0.73, "epsForward": -1.33, "epsCurrentYear": -1.23, "priceEpsCurrentYear": -1.4243902, "sharesOutstanding": 64245700, "bookValue": 0.789, "fiftyDayAverage": 1.31629, "fiftyDayAverageChange": 0.43570995, "fiftyDayAverageChangePercent": 0.33101365, "twoHundredDayAverage": 1.4438425, "twoHundredDayAverageChange": 0.30815744, "twoHundredDayAverageChangePercent": 0.2134287, "marketCap": 112558464, "forwardPE": -1.3172932, "priceToBook": 2.2205324, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "averageAnalystRating": "2.2 - Buy", "tradeable": false, "cryptoTradeable": false, "firstTradeDateMilliseconds": 1390806000000, "priceHint": 4, "regularMarketChange": 0.16600001, "regularMarketDayHigh": 1.752, "regularMarketDayRange": "1.582 - 1.752", "regularMarketDayLow": 1.582, "regularMarketVolume": 2305, "regularMarketPreviousClose": 1.586, "bid": 1.754, "ask": 1.794, "bidSize": 1000, "askSize": 1000, "fullExchangeName": "Frankfurt", "financialCurrency": "USD", "regularMarketOpen": 1.582, "averageDailyVolume3Month": 561, "averageDailyVolume10Day": 0, "fiftyTwoWeekLowChange": 1.2435999, "fiftyTwoWeekLowChangePercent": 2.446105, "fiftyTwoWeekRange": "0.5084 - 3.72", "fiftyTwoWeekHighChange": -1.968, "fiftyTwoWeekHighChangePercent": -0.5290323, "fiftyTwoWeekLow": 0.5084, "fiftyTwoWeekHigh": 3.72, "symbol": "GKO.F"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "9708 Medical Center Drive", "city": "Rockville", "state": "MD", "zip": "20850", "country": "United States", "phone": "240 243 1201", "fax": "301 738 2137", "website": "https://www.glycomimetics.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of glycobiology-based therapies for cancers, including acute myeloid leukemia (AML) and inflammatory diseases with unmet needs in the United States. It is developing uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat AML, as well as in phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and galectin-3 antagonists, a carbohydrate-binding protein. In addition, it is developing GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of cancers that affect the bone and bone marrow, including solid tumors. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.", "fullTimeEmployees": 38, "companyOfficers": [{"maxAge": 1, "name": "Mr. Harout  Semerjian", "age": 52, "title": "CEO, Pres & Director", "yearBorn": 1970, "fiscalYear": 2022, "totalPay": {"raw": 1096122, "fmt": "1.1M", "longFmt": "1,096,122"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 366134, "fmt": "366.13k", "longFmt": "366,134"}}, {"maxAge": 1, "name": "Ms. Rachel K. King", "age": 63, "title": "Co-Founder & Director", "yearBorn": 1959, "fiscalYear": 2022, "totalPay": {"raw": 226433, "fmt": "226.43k", "longFmt": "226,433"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Brian M. Hahn", "age": 48, "title": "Sr. VP & CFO", "yearBorn": 1974, "fiscalYear": 2022, "totalPay": {"raw": 748271, "fmt": "748.27k", "longFmt": "748,271"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Stephanie R. Irish CPA", "age": 51, "title": "VP of Accounting", "yearBorn": 1971, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Christian B. Dinneen-Long", "title": "Gen. Counsel & Company Sec.", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Bruce  Johnson", "age": 54, "title": "Sr. VP & Chief Commercial Officer", "yearBorn": 1968, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Edwin  Rock M.D., Ph.D.", "age": 61, "title": "Sr. VP & Chief Medical Officer", "yearBorn": 1961, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Chinmaya  Rath", "age": 46, "title": "Sr. VP & Chief Bus. Officer", "yearBorn": 1976, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "auditRisk": 6, "boardRisk": 6, "compensationRisk": 8, "shareHolderRightsRisk": 8, "overallRisk": 7, "governanceEpochDate": 1682899200, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}